Subscribe to our Newsletters !!
In tortoises, longevity is an astonishing trait. N
When we picture cutting-edge science, we tend to c
New Delhi – August 23, 2025 – The Association
This year, the Hamburg based life sciences company
Cipla Limited (BSE: 5
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels from the blood of healthy humans.
“According to documented, promising therapeutic possible, locked nucleic acid (LNA)-based anti-miR-92a was further developed and tested in a first in human analysis,” said Stefanie Dimmeler, PhD, Goethe University, Frankfurt, Germany and coauthors. “MRG-110 caused de-repression of gene goals in human peripheral blood cells”
This is an important randomized, double-blind, placebo-controlled, dose-escalating study translating previous work on systemically delivered LNA-modified anti-miR oligonucleotide compounds to efficiently lower miR-92a levels in human peripheral blood,”-Graham C. Parker, PhD, Executive Editor, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children’s Hospital of Michigan, Detroit, MI
Mary Ann Liebert, Inc., Publishers
Abplanalp, W. T., et al. (2020) Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study. Nucleic Acid Therapeutics. doi.org/10.1089/nat.2020.0871.
